CervoMed announces development program, benefits of neflamapimod

CervoMed (CRVO) announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies, DLB, were highlighted in a presentation on advances in DLB drug development by Dr. James Galvin at the 150th Annual American Neurological Association, ANA, conference held September 13-16, 2025 in Baltimore, Maryland. “We are excited to continue showcasing neflamapimod’s promising disease-modifying benefit at ANA. Following the positive data showing neflamapimod reduced the risk of clinically significant worsening on the Clinical Dementia Rating Sum of Boxes in our Phase 2b trial, including a 74% risk reduction relative to placebo in patients who have a low likelihood of having concomitant AD pathology, we are actively preparing to begin a Phase 3 trial in DLB patients and expect to reach alignment on the design of that trial with the U.S. Food and Drug Administration in the fourth quarter of 2025,” said John Alam, MD, Co-Principal Investigator of the RewinD LB trial and CEO of CervoMed. “We are focused on rapidly advancing this potentially effective and tolerable therapeutic agent for a disease state with profound unmet need which is devastating for patients and their families.”